Advertisement

Rheumatology International

, Volume 39, Issue 10, pp 1741–1748 | Cite as

Malignancy risk in Korean male patients with ankylosing spondylitis

  • Bora Nam
  • Hyoungyoung Kim
  • Eun Jin Jang
  • Soo-Kyung Cho
  • Yoon-Kyoung Sung
  • Tae-Hwan KimEmail author
Comorbidities
  • 65 Downloads

Abstract

The objective of this study is to determine the overall and specific cancer risks in male patients with ankylosing spondylitis (AS). From the claims database of the Health Insurance and Review Assessment, male patients with AS without prior cancer history were selected (n = 21,780). Stratified random samples of claims data were used as a reference general male population group (n = 342,361). Incidence rates of overall and types of cancer were presented as number of events per 10,000 person-years with 95% confidence interval (CI). A standardized incidence ratio (SIR) was used to represent the association between AS and cancer, accounting for person-years at risk. Compared to a general male population group, the overall incidence of cancer was increased in male patients with AS (SIR 1.25, 95% CI 1.15–1.36). For specific malignancy types, the risks of male reproductive system malignancy (SIR 1.97, 95% CI 1.59–2.35) and pancreatic cancer (SIR 1.75, 95% CI 1.12–2.37) were increased. Male patients with AS had increased cancer risk, especially for male reproductive system and pancreatic cancer.

Keywords

Ankylosing spondylitis Cancer Risk Standardized incidence ratio 

Notes

Author contributions

Conceptualization: HK, SKC, YKS, THK. Formal analysis: HK, EJJ. Investigation: BN, HK. Methodology: YKS, EJJ. Writing—original draft: BN. Writing—review and editing: YKS, THK.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

To protect patient privacy, the National Health Insurance (NHI) stores beneficiary identifications in an encrypted format and provides data to the public without individual identifiers. Using these data allowed our study to be included in exemption categories (Institutional Review Board file no. HYUH 2018-12-027).

Conflict of interest

The authors have declared no conflicts of interest.

References

  1. 1.
    Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390.  https://doi.org/10.1016/S0140-6736(07)60635-7 CrossRefGoogle Scholar
  2. 2.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to virchow? Lancet 357(9255):539–545.  https://doi.org/10.1016/S0140-6736(00)04046-0 CrossRefGoogle Scholar
  3. 3.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867.  https://doi.org/10.1038/nature01322 CrossRefGoogle Scholar
  4. 4.
    Munn LL (2017) Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med.  https://doi.org/10.1002/wsbm.1370 Google Scholar
  5. 5.
    Yang Z, Lin F, Qin B, Liang Y, Zhong R (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42(2):282–291.  https://doi.org/10.3899/jrheum.140566 CrossRefGoogle Scholar
  6. 6.
    Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212.  https://doi.org/10.1186/s13075-015-0728-9 CrossRefGoogle Scholar
  7. 7.
    Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65(7):1913–1921.  https://doi.org/10.1002/art.37969 CrossRefGoogle Scholar
  8. 8.
    Liang Y, Yang Z, Qin B, Zhong R (2014) Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73(6):1151–1156.  https://doi.org/10.1136/annrheumdis-2013-203305 CrossRefGoogle Scholar
  9. 9.
    Feltelius N, Ekbom A, Blomqvist P (2003) Cancer incidence among patients with ankylosing spondylitis in Sweden 1965–95: a population based cohort study. Ann Rheum Dis 62(12):1185–1188CrossRefGoogle Scholar
  10. 10.
    Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 65(9):1184–1187.  https://doi.org/10.1136/ard.2005.047514 CrossRefGoogle Scholar
  11. 11.
    Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66(5):1282–1290.  https://doi.org/10.1002/art.38339 CrossRefGoogle Scholar
  12. 12.
    Chang CC, Chang CW, Nguyen PA, Chang TH, Shih YL, Chang WY, Horng JT, Lee OK, Ho JH (2017) Ankylosing spondylitis and the risk of cancer. Oncol Lett 14(2):1315–1322.  https://doi.org/10.3892/ol.2017.6368 CrossRefGoogle Scholar
  13. 13.
    Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32(5):718–728.  https://doi.org/10.3346/jkms.2017.32.5.718 CrossRefGoogle Scholar
  14. 14.
    Kim L, Kim JA, Kim S (2014) A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 36:e2014008.  https://doi.org/10.4178/epih/e2014008 CrossRefGoogle Scholar
  15. 15.
    Jung KW, Won YJ, Kong HJ, Lee ES, Community of Population-Based Regional Cancer R (2018) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 50(2):303–316.  https://doi.org/10.4143/crt.2018.143 CrossRefGoogle Scholar
  16. 16.
    Deng C, Li W, Fei Y, Li Y, Zhang F (2016) Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep 6:32063.  https://doi.org/10.1038/srep32063 CrossRefGoogle Scholar
  17. 17.
    Egiziano G, Bernatsky S, Shah AA (2016) Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol 30(1):53–62.  https://doi.org/10.1016/j.berh.2016.03.001 CrossRefGoogle Scholar
  18. 18.
    Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37(1):31–38.  https://doi.org/10.1016/j.semarthrit.2007.01.002 CrossRefGoogle Scholar
  19. 19.
    Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88(5):284–293.  https://doi.org/10.1097/MD.0b013e3181b76ab5 CrossRefGoogle Scholar
  20. 20.
    Baldini C, Pepe P, Luciano N, Ferro F, Talarico R, Grossi S, Tavoni A, Bombardieri S (2012) A clinical prediction rule for lymphoma development in primary Sjogren’s syndrome. J Rheumatol 39(4):804–808.  https://doi.org/10.3899/jrheum.110754 CrossRefGoogle Scholar
  21. 21.
    Alcalay M, Bontoux D, Maire P, Matuchansky C, Alcalay D, Tanzer J (1982) HLA-B27 and colorectal cancer. N Engl J Med 307(7):443–444.  https://doi.org/10.1056/NEJM198208123070718 Google Scholar
  22. 22.
    Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL (2001) Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 115(2):320–322CrossRefGoogle Scholar
  23. 23.
    Hammer RE, Richardson JA, Simmons WA, White AL, Breban M, Taurog JD (1995) High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Investig Med 43(3):262–268Google Scholar
  24. 24.
    Endogenous H, Prostate Cancer Collaborative G, Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100(3):170–183.  https://doi.org/10.1093/jnci/djm323 CrossRefGoogle Scholar
  25. 25.
    Bostwick DG, Cheng L (2012) Precursors of prostate cancer. Histopathology 60(1):4–27.  https://doi.org/10.1111/j.1365-2559.2011.04007.x CrossRefGoogle Scholar
  26. 26.
    Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Rev Urol 6(4):171–179Google Scholar
  27. 27.
    Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202.  https://doi.org/10.1056/nejmoa0908127 CrossRefGoogle Scholar
  28. 28.
    Straub RH, Struharova S, Scholmerich J, Harle P (2002) No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6 Suppl 28):S52–S59Google Scholar
  29. 29.
    Shang Z, Wang X, Yan H, Cui B, Wang Q, Wu J, Cui X, Li J, Ou T, Yang K (2018) Intake of non-steroidal anti-inflammatory drugs and the risk of prostate cancer: a meta-analysis. Front Oncol 8:437.  https://doi.org/10.3389/fonc.2018.00437 CrossRefGoogle Scholar
  30. 30.
    Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388(10039):73–85.  https://doi.org/10.1016/S0140-6736(16)00141-0 CrossRefGoogle Scholar
  31. 31.
    Rudwaleit M, Baeten D (2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 20(3):451–471.  https://doi.org/10.1016/j.berh.2006.03.010 CrossRefGoogle Scholar
  32. 32.
    Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19(4):789–799.  https://doi.org/10.1097/MIB.0b013e31828029c0 CrossRefGoogle Scholar
  33. 33.
    Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, Force USPST (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 146(5):376–389CrossRefGoogle Scholar
  34. 34.
    Flossmann E, Rothwell PM, British Doctors Aspirin T, The UKTIAAT (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369(9573):1603–1613.  https://doi.org/10.1016/S0140-6736(07)60747-8 CrossRefGoogle Scholar
  35. 35.
    Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, Investigators APCS (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884.  https://doi.org/10.1056/NEJMoa061355 CrossRefGoogle Scholar
  36. 36.
    Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT (2010) Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 28(18):2952–2957.  https://doi.org/10.1200/JCO.2009.26.0695 CrossRefGoogle Scholar
  37. 37.
    Burr NE, Talboys RJ, Savva S, Clark A, Phillips M, Metcalfe M, Dennison A, Robinson R, Lewis MP, Rhodes M, Rushbrook S, Hart AR (2014) Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom. Dig Dis Sci 59(7):1567–1572.  https://doi.org/10.1007/s10620-014-3056-z CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of RheumatologyHanyang University Hospital for Rheumatic DiseasesSeoulRepublic of Korea
  2. 2.Department of Information StatisticsAndong National UniversityAndongRepublic of Korea

Personalised recommendations